Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an
excellent safety record. They provide evidence for the long-sought promise of gene therapy …

The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …

Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low
immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease …

Therapeutic vaccines that elicit cytotoxic T cell responses targeting tumor-specific
neoantigens hold promise for providing long-term clinical benefit to patients with cancer …

Summary Background Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically
active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe …

The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based
particle vaccine, RTS, S, which targets the pre-erythrocytic stage of Plasmodium falciparum …

Adenoviral vectors are a safe and potently immunogenic vaccine delivery platform. Non-
replicating Ad vectors possess several attributes which make them attractive vaccines for …

Background The West African outbreak of Ebola virus disease that peaked in 2014 has
caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority …

Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …